Skip to main content

Astrazeneca Plc Ord(AZNCF)
OTC US

Today's Change
Delayed Last Update
Day Low182.2750
Day High187.1000
Open:187.1000
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

Top Stories: Astrazeneca Plc Ord

Select a category then submit the form to load news
Tipranks
AstraZeneca Seeks to Advance Subcutaneous Saphnelo in US After FDA Complete Response
Tipranks
AstraZeneca Confirms Updated Share Capital and Voting Rights
Tipranks
AstraZeneca’s Imfinzi Wins Key EU Backing for First Perioperative Immunotherapy in Early Gastric Cancer
Tipranks
AstraZeneca Joins NYSE With Harmonised Global Listing to Broaden Investor Base
Tipranks
AstraZeneca Strikes $1.2bn CSPC Deal to Bolster Obesity Drug Portfolio
Tipranks
AstraZeneca Unveils $15bn China Investment to Expand Next-Generation Drug Capabilities
Tipranks
J.P. Morgan Sticks to Its Buy Rating for AstraZeneca (AZN)
Tipranks
Berenberg Bank Sticks to Their Buy Rating for AstraZeneca (AZN)
Tipranks
Goldman Sachs Sticks to Its Buy Rating for AstraZeneca (AZN)
Tipranks
Berenberg Bank Keeps Their Buy Rating on AstraZeneca (AZN)
Tipranks
Bank of America Securities Initiates a Buy Rating on AstraZeneca (AZN)
Tipranks
Shore Capital Sticks to Its Buy Rating for AstraZeneca (AZN)
Tipranks
Deutsche Bank Sticks to Their Sell Rating for AstraZeneca (AZN)
Tipranks
UBS Reaffirms Their Buy Rating on AstraZeneca (AZN)
Tipranks
Barclays Sticks to Its Buy Rating for AstraZeneca (AZN)
Tipranks
J.P. Morgan Remains a Buy on AstraZeneca (AZN)
Tipranks
Berenberg Bank Remains a Buy on AstraZeneca (AZN)
Tipranks
AstraZeneca (AZN) Gets a Buy from Barclays
Tipranks
J.P. Morgan Sticks to Its Buy Rating for AstraZeneca (AZN)
Tipranks
AstraZeneca Confirms Total Voting Rights of 1.55 Billion Shares
Tipranks
AstraZeneca Discloses Routine Share Sale by Non-Executive Director
Tipranks
Enhertu Wins US Breakthrough Status in High‑Risk Early HER2‑Positive Breast Cancer
Tipranks
AstraZeneca Discloses Director’s Gift of Shares to Spouse
Tipranks
AstraZeneca (AZN) Gets a Sell from Deutsche Bank
Tipranks
AstraZeneca’s Saphnelo Gains EU Approval for Self-Administration in Lupus Treatment
Tipranks
TD Cowen Remains a Buy on AstraZeneca (AZN)
Tipranks
AstraZeneca (AZN) Receives a Rating Update from a Top Analyst
Tipranks
AstraZeneca Announces Updated Share Capital and Voting Rights
Tipranks
Deutsche Bank Sticks to Their Sell Rating for AstraZeneca (AZN)
Tipranks
Capital Group Increases Stake in AstraZeneca
Tipranks
AstraZeneca CFO Sells 15,000 American Depositary Shares
Tipranks
Deutsche Bank Remains a Sell on AstraZeneca (AZN)

Profile

AstraZeneca PLC was incorporated in England and Wales on 17 June 1992. From February 1993 until April 1999, the Company was called Zeneca Group PLC. On 6 April 1999, the Company changed its name to AstraZeneca PLC. It is a biopharmaceutical company. The Company focuses on three important areas of healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). The Company is also engaged in the Infection, Neuroscience and Gastrointestinal (ING) disease areas. It operates in more than 100 countries.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.